CLDX
HEALTHCARECelldex Therapeutics Inc
AI Insight
What's Moving CLDX Today?
No stock-specific AI insight has been generated for CLDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$19.52$35.79
$32.98
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-4.27
Dividend Yield—
Dividend / Share—
ROE-48.9%
Profit Margin—
Debt / Equity—
Trading
Volume670K
Avg Volume (10D)—
Shares Outstanding78.5M
CLDX News
23 articles- Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth EstimatesTradingKey·Jun 18, 2026
- Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price MomentumYahoo Finance·Jun 15, 2026
- Barzolvolimab leaves 64% of CSU patients angioedema-free 7 months after dosingStock Titan·Jun 14, 2026
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual MeetingYahoo Finance Singapore·Jun 14, 2026
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswire Inc.·Jun 14, 2026
- Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswire Inc.·Jun 14, 2026
- Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual CongressYahoo Finance·Jun 10, 2026
- [Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·May 19, 2026
- Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed SignalsYahoo Finance·May 12, 2026
- Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Celldex Reports First Quarter Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Innoviva (INVA) Tops Q1 Earnings EstimatesYahoo Finance·May 7, 2026
- Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?Yahoo Finance·May 4, 2026
- Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price JumpYahoo Finance·Apr 25, 2026
- Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast EnrollmentMarketbeat·Apr 15, 2026
- Celldex to Present at Upcoming Investor ConferenceYahoo Finance·Apr 13, 2026
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire Inc.·Apr 6, 2026
- Celldex shares plunge after dumping $300 million stock dealYahoo Finance·Apr 2, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Escalation Signals in Iran Conflict Lift Oil PricesYahoo Finance·Apr 2, 2026
- Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX?Yahoo Finance·Apr 2, 2026
- Celldex Announces Pricing of $300 Million Public Offering of Common StockGlobeNewswire Inc.·Apr 2, 2026
- Celldex Announces Proposed Public Offering of Common StockYahoo Finance·Apr 1, 2026
- Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026Yahoo Finance·Mar 27, 2026
All 23 articles loaded
Price Data
Open$32.87
Previous Close$33.41
Day High$33.72
Day Low$32.57
52 Week High$35.79
52 Week Low$19.52
52-Week Range
$19.52$35.79
$32.98
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-4.27
Dividend Yield—
Dividend / Share—
ROE-48.9%
Profit Margin—
Debt / Equity—
Trading
Volume670K
Avg Volume (10D)—
Shares Outstanding78.5M
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—